160 related articles for article (PubMed ID: 34720809)
1. Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer.
Reinisch M; Marschner N; Otto T; Korfel A; Stoffregen C; Wöckel A
Breast Care (Basel); 2021 Oct; 16(5):491-499. PubMed ID: 34720809
[TBL] [Abstract][Full Text] [Related]
2. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
3. Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany.
Hofheinz R; Clouth J; Borchardt-Wagner J; Wagner U; Weidling E; Jen MH; Brück P
BMC Cancer; 2016 Dec; 16(1):937. PubMed ID: 27923357
[TBL] [Abstract][Full Text] [Related]
4. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
5. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
[TBL] [Abstract][Full Text] [Related]
7. Generating Individual Patient Preferences for the Treatment of Osteoarthritis Using Adaptive Choice-Based Conjoint (ACBC) Analysis.
Al-Omari B; Sim J; Croft P; Frisher M
Rheumatol Ther; 2017 Jun; 4(1):167-182. PubMed ID: 28255898
[TBL] [Abstract][Full Text] [Related]
8. Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study.
Mansfield C; Botha W; Vondeling GT; Klein K; Wang K; Singh J; Hackshaw MD
Breast Cancer; 2023 Jan; 30(1):23-35. PubMed ID: 36074320
[TBL] [Abstract][Full Text] [Related]
9. Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis.
Bridges JF; Mohamed AF; Finnern HW; Woehl A; Hauber AB
Lung Cancer; 2012 Jul; 77(1):224-31. PubMed ID: 22369719
[TBL] [Abstract][Full Text] [Related]
10. Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan.
Omori Y; Enatsu S; Cai Z; Ishiguro H
Breast Cancer; 2019 Sep; 26(5):652-662. PubMed ID: 30949915
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
12. Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment.
Janse S; Janssen E; Huwig T; Basu Roy U; Ferris A; Presley CJ; Bridges JFP
Curr Med Res Opin; 2021 Apr; 37(4):643-653. PubMed ID: 33571024
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study.
Hsieh HH; Wu TY; Chen CH; Kuo YH; Hour MJ
Ther Adv Drug Saf; 2023; 14():20420986231181338. PubMed ID: 37359444
[TBL] [Abstract][Full Text] [Related]
14. Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer.
Hurvitz SA; Lalla D; Crosby RD; Mathias SD
Breast Cancer Res Treat; 2013 Dec; 142(3):603-9. PubMed ID: 24218050
[TBL] [Abstract][Full Text] [Related]
15. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
[TBL] [Abstract][Full Text] [Related]
16. Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole
Jhaveri K; O'Shaughnessy J; Fasching PA; Tolaney SM; Yardley DA; Sharma VK; Biswas C; Thuerigen A; Pathak P; Rugo HS
Ther Adv Med Oncol; 2023; 15():17588359231216095. PubMed ID: 38107828
[TBL] [Abstract][Full Text] [Related]
17. Real-World First-Line Treatment Patterns and Outcomes in Hormone Receptor-Positive Advanced Breast Cancer Patients: A Multicenter, Retrospective Study in China.
Chen Z; Ouyang Q; Wang Y; Wang J; Wang H; Wu X; Zhang P; Huang J; Zheng Y; Cao W; Shao X; Xie N; Tian C; Liang H; Wang C; Zhang Y; Ren D; Wang X
Front Oncol; 2022; 12():829693. PubMed ID: 35311126
[TBL] [Abstract][Full Text] [Related]
18. Patient, physician, and general population preferences for treatment characteristics in relapsed or refractory chronic lymphocytic leukemia: A conjoint analysis.
Landfeldt E; Eriksson J; Ireland S; Musingarimi P; Jackson C; Tweats E; Gaudig M
Leuk Res; 2016 Jan; 40():17-23. PubMed ID: 26654707
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy and radiotherapy for advanced pancreatic cancer.
Chin V; Nagrial A; Sjoquist K; O'Connor CA; Chantrill L; Biankin AV; Scholten RJ; Yip D
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011044. PubMed ID: 29557103
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
